StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Up 2.5%

Shares of NASDAQ:TRVN opened at $1.21 on Wednesday. Trevena has a 12-month low of $0.95 and a 12-month high of $10.99. The company’s 50 day moving average price is $1.27 and its two-hundred day moving average price is $1.56. The firm has a market cap of $1.05 million, a PE ratio of -0.03 and a beta of 0.87.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.